Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Construction in Progress: 2014-2018

Historic Construction in Progress for Lineage Cell Therapeutics (LCTX) over the last 4 years, with Dec 2018 value amounting to $1.3 million.

  • Lineage Cell Therapeutics' Construction in Progress was N/A to $8.9 million in Q1 2019 from the same period last year, while for Mar 2019 it was $8.9 million, marking a year-over-year change of. This contributed to the annual value of $1.3 million for FY2018, which is 77.08% down from last year.
  • As of FY2018, Lineage Cell Therapeutics' Construction in Progress stood at $1.3 million, which was down 77.08% from $5.5 million recorded in FY2017.
  • Lineage Cell Therapeutics' 5-year Construction in Progress high stood at $5.5 million for FY2017, and its period low was $93,000 during FY2015.
  • Moreover, its 2-year median value for Construction in Progress was $3.4 million (2017), whereas its average is $3.4 million.
  • Data for Lineage Cell Therapeutics' Construction in Progress shows a maximum YoY crashed of 77.09% (in 2015) over the last 5 years.
  • Over the past 4 years, Lineage Cell Therapeutics' Construction in Progress (Yearly) stood at $406,000 in 2014, then slumped by 77.09% to $93,000 in 2015, then reached $5.5 million in 2017, then slumped by 77.08% to $1.3 million in 2018.